Verifying…
Home / Registered in Nigeria / Advant Tablet 8 mg

Advant Tablet 8 mg

NAFDAC Reg. No. A4-9123 · Drug

Registered with NAFDAC. Registration activeAs of 31 October 2026 · synced automatically from official sources.
Product
Advant Tablet 8 mg
NAFDAC number
A4-9123
Active ingredient
Candesartan Cilexetil
Strength
8 mg
Form
Tablet
Pack size
2 x 7's; 4 x 7's (in Alu-Alu blisters)
Manufacturer
Not listed
Applicant (holder)
Getz Pharma Nigeria Limited
Approved
25 May 2023
Status
Active View on NAFDAC ↗
Registration valid to
24 May 2028
WHO alerts
None found
Community reports
None
Times checked
0

About the medicine: Candesartan cilexetil: uses, dosage and brands worldwide

What we found

  • Advant Tablet 8 mg is on the NAFDAC register with an active registration (A4-9123). A valid number alone does not prove a pack is genuine — counterfeiters copy real numbers, so also check the expiry date, seal and print quality.

Generated automatically from the NAFDAC register, WHO alerts and community data as of today. This is not medical advice. Always follow your doctor or pharmacist.

How to use Advant Tablet 8 mg

What the official label says. If a doctor prescribed it, follow the prescription. Your pack's leaflet comes first if it is different.

Serious warning: FETAL TOXICITY • When pregnancy is detected, discontinue candesartan cilexetil tablets as soon as possible [see Warnings and Precautions (5.1) and Use in Specific Populations (8.1)]. • Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus [see Warnings and Precautions (5.1) and Use in Specific Populations (8.1)]. WARNING: FETAL TOXICITY See full prescribing information for complete boxed warning. …
Who it is for

Candesartan cilexetil tablets are an angiotensin II receptor blocker (ARB) indicated for: · Treatment of hypertension in adults and children 1 to

How to take it and how often
  • Starting Dose Target Dose Adult Hypertension 16 mg tablet once daily 8 to 32 mg tablet total daily dose Pediatric Hypertension (1 to ˂6 years) 0.2 mg/kg oral suspension once daily 0.05 to 0.4 mg/kg oral suspension once daily or consider divided dose Pediatric Hypertension (6 to ˂17 years) 50 kg 8 to 16 mg tablet once daily 50 kg 4 to 32 mg tablet once daily or consider divided dose Adult Heart Failure 4 mg tablet once daily 1 The target dose is 32 mg once daily, which is achieved by doubling the dose at approximately 2-week intervals, as tolerated by patient Adult Hypertension Dosage must be individualized
  • Blood pressure response is dose related over the range of 2 to 32 mg
  • The usual recommended starting dose of candesartan cilexetil tablet is 16 mg once daily when it is used as monotherapy in patients who are not volume depleted
  • Candesartan cilexetil tablets can be administered once or twice daily with total daily doses ranging from 8 mg to 32 mg
  • Larger doses do not appear to have a greater effect, and there is relatively little experience with such doses
  • Most of the antihypertensive effect is present within 2 weeks, and maximal blood pressure reduction is generally obtained within 4 to 6 weeks of treatment with candesartan cilexetil tablets
  • Use in Hepatic Impairment: Initiate with 8 mg candesartan cilexetil tablets in patients with moderate hepatic insufficiency
  • Dosing recommendations cannot be provided for patients with severe hepatic insufficiency [see Clinical Pharmacology ] . …
Strengths it comes in

32 mg are light pink, round, biconvex, uncoated mottled tablets debossed with ‘L171’on one side and scoring on other side. Tablets 32 mg (3).

Children

The antihypertensive effects of candesartan cilexetil were evaluated in hypertensive children 1 to

While you are taking it
  • Advise patient to read FDA-approved patient labeling (Patient Information)
  • Pregnancy Advise female patients of childbearing age about the consequences of exposure to candesartan cilexetil tablets during pregnancy
  • Discuss treatment options with women planning to become pregnant
  • Tell patients to report pregnancies to their physicians as soon as possible
  • Manufactured by: Alembic Pharmaceuticals Limited (Formulation Division), Panelav 389350, Gujarat, India Manufactured for: Alembic Pharmaceuticals, Inc
  • Bedminster, NJ 07921, USA Revised: 07/2021
Talk to a doctor first if
  • Candesartan cilexetil tablets are contraindicated in patients who are hypersensitive to candesartan
  • Do not co-administer aliskiren with candesartan cilexetil tablets in patients with diabetes [see Drug Interactions ]
  • Known hypersensitivity to product components
  • Do not co-administer aliskiren with candesartan cilexetil tablets in patients with diabetes
Medicines it may not mix with

· Lithium: Increases in serum lithium concentrations and toxicity (7). · NSAIDs use may lead to increased risk of renal impairment and loss of antihypertensive effect (7). · Dual inhibition of the renin- angiotension system: Increased risk of renal impairment, hypotension, and hyperkalemia (7) . • Combined inhibition of the renin-angiotensin system: Increased risk of renal impairment, hypotension, and hyperkalemia (7). 7.1 Agents Increasing Serum Potassium Co-administration of candesartan cilexetil with potassium sparing diuretics, potassium supplements, potassium-containing salt substitutes or other drugs that raise serum potassium levels may result in hyperkalemia. …

Warnings

5.1 Fetal Toxicity Candesartan cilexetil tablets can cause fetal harm when administered to a pregnant woman. Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. Resulting oligohydramnios can be associated with fetal lung hypoplasia and skeletal deformations. Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure and death. When pregnancy is detected, discontinue candesartan cilexetil tablets as soon as possible [see Use in Specific Populations (8.1)]. 5.2 Morbidity in Infants Children

Possible side effects

· Most common adverse reactions which caused adult patients to discontinue therapy for: o Hypertension were headache (0.6%) and dizziness (0.3%) (6.1). o Heart Failure were hypotension (4.1%) (5.3), abnormal renal function (6.3%) (5.4), and hyperkalemia (2.4%) (5.5). To report SUSPECTED ADVERSE REACTIONS, contact Alembic Pharmaceuticals Limited at 1-866-210-9797 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. …

Pregnancy and breastfeeding

8.1 Pregnancy Risk Summary Candesartan cilexetil can cause fetal harm when administered to a pregnant woman. Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. …

If you take too much

No lethality was observed in acute toxicity studies in mice, rats, and dogs given single oral doses of up to 2000 mg/kg of candesartan cilexetil. In mice given single oral doses of the primary metabolite, candesartan, the minimum lethal dose was greater than 1000 mg/kg but less than 2000 mg/kg. The most likely manifestation of overdosage with candesartan cilexetil would be hypotension, dizziness, and tachycardia; bradycardia could occur from parasympathetic (vagal) stimulation. If symptomatic hypotension should occur, supportive treatment should be instituted. …

If you miss a dose

Take it when you remember, unless it is nearly time for the next dose. Then skip the missed one. Never take two doses at once to make up for it. Check your leaflet, as some medicines are different.

From the official U.S. FDA label for this active ingredient. Your pack may have a different strength, so always read its leaflet. If a doctor prescribed it, follow the prescription. Ask a pharmacist if you are unsure. Label dated 2021-10-04.

Label for candesartan cilexetil, the active ingredient registered with NAFDAC.

Check your pack of Advant Tablet 8 mg

Add the expiry date on your pack for a full Trust Score.

Or take photos of the pack
3 free checks left today Official sources: U.S. FDA · EMA (EU) · NAFDAC · WHO alerts

About Advant Tablet 8 mg

What is in Advant Tablet 8 mg?

Advant Tablet 8 mg contains Candesartan Cilexetil (8 mg), as tablet, according to its NAFDAC registration record.

Is Advant Tablet 8 mg registered with NAFDAC?

Yes. Advant Tablet 8 mg is listed on the NAFDAC register under registration number A4-9123, and its registration is active as of 31 October 2026.

Has Advant Tablet 8 mg been flagged as fake or recalled?

No WHO falsified or substandard medical product alert currently matches Advant Tablet 8 mg in our automatically synced alert list.

How can I check that my pack of Advant Tablet 8 mg is genuine?

Run a free authenticity scan with the NAFDAC number A4-9123, your pack's expiry date and batch number to get a Trust Score, compare the pack with the NAFDAC record (ingredient, strength, form, manufacturer), and buy only from licensed pharmacies.

How do I take Advant Tablet 8 mg?

Follow your prescription or the leaflet in your pack. The official label says: Starting Dose Target Dose Adult Hypertension (2.1) 16 mg tablet once daily 8 to 32 mg tablet total daily dose Pediatric Hypertension (1 to ˂6 years) (2.2) 0.2 mg/kg oral suspension once daily 0.05 to 0.4 mg/kg oral suspension once daily or consider divided dose Pediatric Hypertension (6 to ˂17 years) (2.2) 50 kg 8 to 16 mg tablet once daily 50 kg 4 to 32 mg tablet once daily or…

What is Advant Tablet 8 mg used for?

Candesartan cilexetil tablets are an angiotensin II receptor blocker (ARB) indicated for: · Treatment of hypertension in adults and children 1 to (Summarised from the official U.S. FDA label for candesartan cilexetil. Always follow your doctor or pharmacist.)

Patient reviews

–No reviews yet
5★
0
4★
0
3★
0
2★
0
1★
0
Have you used Advant Tablet 8 mg? Share your experience to help other patients. Sign in to review

Reviews are personal experiences from PillVera users, not medical advice. Report side effects to your doctor and to NAFDAC.